May 27, 2014:

The Big Ten Cancer Research Consortium (BTCRC) announces the appointment of Susan Goodin, PharmD, as executive officer of the consortium.

Dr. Goodin is executive director of statewide affairs at Rutgers Cancer Institute of New Jersey and professor of medicine at Rutgers Robert Wood Johnson Medical School. She possesses more than 20 years of clinical research leadership experience including serving as the deputy director of operations, associate director of clinical trials and therapeutics, and director of the Division of Pharmaceutical Sciences at the Cancer Institute of New Jersey. She played a key role in the establishment of the Cancer Institute’s clinical practice and designed its clinical research infrastructure, including the Center’s research office, research pharmacy, and protocol review and monitoring system. Dr. Goodin is a founding co-leader of the Cancer Institute of New Jersey’s statewide clinical trials network that includes 15 hospitals under the Center’s clinical research infrastructure.

As executive officer of the Big Ten CRC, Dr. Goodin will work closely with the consortium’s administrative headquarters, pharmaceutical partners, and other physicians and researchers to carry out the consortium’s mission. She will serve as the primary spokesperson and representative for the consortium at meetings and events with funders and professional organizations, and will communicate regularly with Big Ten CRC cancer center directors and the steering committee regarding key issues, challenges, and opportunities facing the consortium.

“I am honored to have been chosen to serve as the executive officer of the Big Ten Cancer Research Consortium, an elite group of academic institutions,” stated Dr. Goodin. “In an era when targeted cancer treatments are no longer a prediction but a reality, these centers will incorporate their groundbreaking science into novel clinical trials. Working together as a consortium will yield impactful results at even a greater speed.”

Dr. Goodin’s research activities have focused predominantly on the development of pharmaceutical interventions, including both prevention and therapeutics. She has served as principal investigator on numerous clinical trials, including investigator-initiated, multi-center investigator-initiated, and industry-initiated trials and has an extensive record of securing funding from government, pharmaceutical, philanthropic, and intramural sources. She has published in prestigious journals such as the Journal of Clinical Oncology, Journal of Oncology Practice, American Journal of Health System Pharmacy, Cancer Epidemiological Biomarkers and Prevention, and Clinical Cancer Research and currently serves on the editorial board of Clinical Therapeutics and is a journal reviewer for New England Journal of Medicine, Clinical Cancer Research, and Clinical Therapeutics, among others.

Dr. Goodin has presented nationally on the topics of cancer treatment, chemoprevention, and supportive care. She is an active member or board member of the Board of Pharmacy Specialties, American Society of Health-System Pharmacists, American College of Clinical Pharmacy, American Society of Clinical Oncology, and the International Society of Oncology Pharmacy Practice.

Dr. Goodin attended the University of Kentucky, where she earned a Doctor of Pharmacy degree after completing her Bachelor of Science in Pharmacy. She joined Rutgers Cancer Institute of New Jersey in 1993.

Dr. Goodin’s appointment comes at time of significant growth as the Big Ten CRC is actively developing several clinical trial concepts through various working groups. These disease-specific groups include physicians or researchers from each member institution with expertise in genitourinary, gastrointestinal, thoracic, and breast cancers. The consortium anticipates further expansion of these working groups to include additional cancer types.

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium creates a unique team-research culture to drive science rapidly from ideas to treatment-changing paradigms. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in student-athletes’ lives and emphasize the values of integrity, fairness and competitiveness. The broad-based athletic programs of the 12 Big Ten institutions provide in excess of $141 million in direct financial aid to more than 8,200 student-athletes playing on more than 300 teams in 43 different sports. The Big Ten sponsors 26 official conference sports, 13 for men and 13 for women, and will add men’s and women’s lacrosse as the 27th and 28th official sports for the 2014-15 academic year. For more information, visit www.bigten.org.